Roche: Gazyvaro approved by EMA
(CercleFinance.com) - Roche today announced that the European Medicines Agency (EMA) has approved a new 90 minute shorter infusion time for Gazyvaro (obinutuzumab) in combination with chemotherapy in patients with previously treated or untreated advanced follicular lymphoma (FL).
"The regular rate of infusion can take approximately three to four hours, so administering over a shorter time period can result in time savings for patients and could also reduce pressure on healthcare systems. This is especially important given the ongoing challenges for healthcare systems around the world brought about by the COVID-19 pandemic," the group said.
"Gazyvaro has improved outcomes for people with follicular lymphoma, and now has the additional benefit of a shorter infusion time", said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
"The regular rate of infusion can take approximately three to four hours, so administering over a shorter time period can result in time savings for patients and could also reduce pressure on healthcare systems. This is especially important given the ongoing challenges for healthcare systems around the world brought about by the COVID-19 pandemic," the group said.
"Gazyvaro has improved outcomes for people with follicular lymphoma, and now has the additional benefit of a shorter infusion time", said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development.
Copyright (c) 2021 CercleFinance.com. All rights reserved.